| 0.1205 0.121 (0%) | 07-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.23 |
1-year : | 0.27 |
| Resists | First : | 0.2 |
Second : | 0.23 |
| Pivot price | 0.03 |
|||
| Supports | First : | 0.08 |
Second : | 0 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.03 |
| MA(100) : | 0.02 |
MA(250) : | 0.16  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.4 |
D(3) : | 70.8 |
| RSI | RSI(14): 89.9 |
|||
| 52-week | High : | 0.46 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ONCR ] has closed above the upper band by 3.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 801.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.2 - 0.2 | 0.2 - 0.2 |
| Low: | 0.12 - 0.12 | 0.12 - 0.12 |
| Close: | 0.12 - 0.13 | 0.13 - 0.13 |
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Mon, 03 Jul 2023
Biotech layoffs 2023: In Q2, more than 700 Boston-area life science jobs were cut - The Business Journals
Mon, 12 Jun 2023
After layoffs leave Oncorus a 'shell' of a company, board liquidates the business - Fierce Biotech
Fri, 02 Jun 2023
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace
Fri, 02 Jun 2023
Facing bankruptcy, RNA-focused Oncorus lays off 'substantially' all its staff - Fierce Biotech
Wed, 30 Nov 2022
Oncorus drops HSV solid tumor prospect, lays off 15% of workforce - Fierce Biotech
Fri, 07 Oct 2022
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer - Nature.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 448 (K) |
| Shares Short P.Month | 164 (K) |
| EPS | -3.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -124.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0.14 |
| Forward Dividend | 0 |
| Dividend Yield | 111.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|